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adsorption of circulating endotoxins in the blood. Toraymyxin â (Toray Medical Co., Ltd, Tokyo, Japan) has been developed as a direct hemoperfusion column that contains polymyxin B-immobilized fiber to bind endotoxins in patients' blood.
A narrative literature review was carried out using PubMed, MEDLINE and Google scholar search engines regarding PMX (defined as direct hemoperfusion with Toraymyxin). We describe the history of the development of Toraymyxin and comment on its clinical efficacy and current status with respect to its use for the treatment of severe sepsis and septic shock. A phase I clinical study was started in 1989, and the first clinical report of 16 patients with septic multiple organ failure treated with PMX was published in 1994. 3 PMX was approved by the Japanese National Health Insurance system for the treatment of endotoxemia and septic shock in 1994. 4 Since then, Toraymyxin has been safely used in more than 100 000 cases in emergency and intensive care units in Japan.
| HISTORY OF THE DEVELOPMENT OF TORAYMYXIN
Toraymyxin received the CE mark of approval in Europe in 1998.
Results of the first preliminary randomized controlled trial (RCT) in
Europe were published in 2005, showing that treatment with PMX was safe and improves cardiac and renal dysfunction in patients with sepsis or septic shock. 5 The findings of a meta-analysis demonstrated the favorable effects of PMX in 2007. 6 The results of a subsequent RCT in Europe, the EUPHAS study (Early Use of Polymyxin B Hemoperfusion in Abdominal Sepsis), which was conducted in Italy, were published in 2009, showing that PMX results in a significant reduction in sepsis-associated mortality. 7 A large RCT, the
ABDO-MIX trial (Effects of Hemoperfusion with a Polymyxin B
Membrane in Peritonitis with Septic Shock) in France, failed to show a survival benefit and improvement in organ failure with PMX compared to the conventional treatment of peritonitis-induced septic shock. 8 Another large RCT, the EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in an RCT of Adults Treated for Endotoxemia and Septic Shock) in the USA and Canada, 9 is closed to new patients and analysis is ongoing.
Toraymyxin is currently available for use in clinical settings in 12 countries outside of Japan (Italy, Spain, Russia, India, Switzerland, Austria, Korea, Taiwan, Saudi Arabia, Slovenia, Thailand, and Turkey) ( Figure 1 ).
| TORAYMYXIN (POLYMYXIN B-IMMOBILIZE D FIBER COLUMN)
Toraymyxin comprises a plastic column containing a knitted roll of polymyxin B-immobilized fiber fabric for human use. To enable the selective adsorption of circulating endotoxins in the blood, polymyxin B was covalently immobilized on the surface of polystyrenederived polypropylene-reinforced conjugated carrier fibers (Figure 2) . 10 There are three types of Toraymyxin columns currently available for clinical use in Japan: PMX-20R â (volume, 135 mL), PMX-05R â (40 mL), and PMX-01R â (8 mL) ( Figure 3 ). The first Toraymyxin column to be released was PMX-20R, which was developed for the treatment of septic shock in adults. 4 The second column to be released was PMX-05R in 2005, which was developed for use in pediatric or elderly patients with smaller circulating blood volumes or bodyweight less than 40 kg. 11 Several reports have shown acceptable results by using PMX-05R in pediatric or elderly patients with sepsis. 11 PMX-01R was released for use in newborn or premature infants in 2011. There are a few case reports describing successful clinical experience with the use of PMX-01R in patients with severe sepsis and a bodyweight less than 1000 g. 12, 13 Since 1994, Toraymyxin has been used in over 100 000 cases in Japan. There have been no reports of any serious adverse effects.
Despite adverse effects such as clotting of cartridges, thrombocytopenia or hypotension being reported, these incidents are rare. 4 The Toraymyxin column was originally designed to specifically adsorb endotoxins. Plasma endotoxin levels are significantly decreased immediately after PMX compared with pretreatment levels ( Figure 4A ). Furthermore, the patients' hyperdynamic state, which is characterized by an increase in cardiac index during endotoxic shock, was returned to normal after treatment ( Figure 4B ). Recently, a new rapid assay called the endotoxin activity assay (EAA) had been developed, which detects endotoxins in whole blood by using autologous neutrophil-dependent chemiluminescence. 16 The There are four RCT conducted outside of Japan as listed in P=.032 at day 1 and day 2, respectively), left ventricular stroke work index (P=.015 at day 2), and oxygen delivery index (P=.007 at day 2) compared with controls. Furthermore, the need for continuous renal replacement therapy (CRRT) after study entry was significantly reduced in the PMX group (P=.043). There were no statistically significant differences in the change in endotoxin or interleukin (IL)-6 levels, organ dysfunction as assessed using the SOFA scores, or 28-day mortality. Together, these results showed that PMX treatment was safe and that it improved cardiac and renal dysfunction as a result of sepsis or septic shock. P<.001). Although the goal was to enrol 120 patients in this study, interim analysis revealed that the risk of mortality in the conventional treatment group was significantly higher than in the PMX group; thus, the EUPHAS study was terminated halfway. A Cox proportional hazard analysis was used for survival analysis in the EUPHAS study; however, some researchers questioned the analytical approach used in this study. 21 Despite the problem of statistical analysis on mortality, the high mortality rate in the conventional treatment group and the lack of evaluation of circulating endotoxin levels, this study demonstrated improvement in hemodynamic conditions in patients with severe sepsis and septic shock as primary endpoints of an RCT conducted outside of Japan.
The ABDO-MIX trial was conducted in France. 8 A total of 243 patients with peritonitis-induced septic shock from abdominal infections were enrolled, and the primary endpoint of the study was the 28-day mortality. No significant increase in mortality or improvement in organ failure in patients treated with PMX was observed compared to conventional therapy for peritonitis-induced septic shock.
However, major differences in the mortality rate and completion rate of two scheduled sessions of PMX among previous trials have since been reported. 22 The 28-day mortality rate recorded in both groups was significantly lower than that reported in larger studies (between 32.7 and 53% for similar patient cohorts). 23, 24 Furthermore, only 81 of the 119 treated patients (68%) completed the two scheduled sessions of PMX. All patients enrolled in the previously published EUPHAS study had completed the two planned sessions of PMX with higher mortality observed in the control group. 22 The incidence of cartridge clotting in the ABDO-MIX study (11.4%; 25/220 sessions) was higher than in previous reports, such as 5.8% (4/68 sessions) in the EUPHAS study 7 and 1.0% (12/1152 sessions) in the EUPHAS 2 study. 25 Clotting problems in the blood circuit during PMX were seldom raised in Japan. The cause of death was also not clarified between the PMX and conventional groups in this study. As such, the conflicting results of the ABDO-MIX study were inconclusive and not definitive.
The EUPHRATES trial conducted in the USA and Canada 9 was designed to address the criticisms of previous studies. Circulating Medicine. 26 The primary endpoint of mortality rate (44.3% in placebo group and 43.75% in PMX group) was not met in full intention-to-treat populations. Analyses of the secondary endpoints in this study are still ongoing and will be reported in the near future.
In their latest meta-analysis, Terayama et al. 27 recently demonstrated that PMX was associated with a lower mortality (risk ratio, =60%). They discussed that a meta-regression analysis revealed a significant negative slope between effect size of PMX therapy and baseline mortality rate in individual studies. Further, in this meta-analysis, they suggested that a beneficial effect with PMX might be greater in patients with higher baseline mortality risk. 27 The effect of postoperative PMX on mortality in patients with septic shock as a result of lower gastrointestinal tract perforation was examined by propensity-matched analysis using the Japanese Diagnosis Procedure Combination (DPC) inpatient database. 28 The 28-day mortality in the PMX group (17.1%; 101/590) was not significantly different from that of the control group (16.3%; 96/590) (P=.696). 28 The effect of PMX on mortality in patients with septic shock requiring CRRT was also examined using the DPC database, demonstrating CVI, cardiovascular index; EEA, endotoxin activity assay; IL-6, interleukin 6; MAP, mean arterial pressure; MODS, multiple organ dysfunction score; PMX, direct hemoperfusion with Toraymyxin; RCT, randomized controlled trial; RRT, renal replacement therapy; SOFA, Sequential Organ Failure Assessment.
that the 28-day mortality in the PMX group (40.2%; 393/978) was significantly lower than that in the control group (46.8%; 458/978) (P=.003). 29 Therefore, the mortality rate in the control group was lower (16.3%) in patients with lower gastrointestinal tract perforation than in patients requiring CRRT (46.8%). These large-scale retrospective studies also seemed to support the fact that PMX might be effective in patients with a higher baseline mortality risk.
The combination of PMX and continuous hemodiafiltration (CHDF) as CRRT appears to be more beneficial for patients with septic renal dysfunction than CHDF alone; combination treatment significantly decreases the concentration of circulating IL-6 and improves patient survival ( Figure 6A ). 30 Moreover, PMX followed by CHDF with a polymethyl methacrylate (PMMA) membrane significantly decreased the concentrations of plasminogen activator inhibitor-1, protein C, interleukin-6, and endogenous anandamide compared to PMX followed by CHDF with a polyacrylonitrile membrane in patients with septic shock. 31 Therefore, the combination of PMX with PMMA-CHDF is beneficial for patients with septic shock and septic acute kidney injury (AKI). In combination therapy, the Toraymyxin column is generally placed before or after CHDF on a single circuit. However, when CHDF cannot be interrupted, for example, in patients with severe renal failure, the Toraymyxin circuit can be connected in parallel or in series with the CHDF circuit ( Figure 6B ). 32 The latest meta-analysis 27 and large-scale retrospective studies 28, 29 suggested that a beneficial effect with PMX might be higher in patients with a higher baseline mortality risk; such Originally, the treatment duration of PMX was set at 2 hours following the results seen in preclinical studies ( Figure 3 ). Endotoxin adsorption capacity is considered to reach equilibrium at 2 hours after the initiation of perfusion; however, the evident clinical efficacy of longer duration of PMX (>6 hours) has been reported in cases lacking clinical efficacy within 2 hours. [33] [34] [35] Mitaka et al. 33 have compared clinical data for patients with a longer duration of PMX (16.9AE7.0 hours) with data for patients with the standard 2-h duration. Yamashita et al. 35 recently showed that a longer duration of PMX might improve the hemodynamics and pulmonary oxygenation capacity in patients without a favorable response to the 2-h PMX.
Adverse effects such as thrombocytopenia have not been reported despite a longer duration of PMX. 33, 34 The four RCT listed in Table 1 used the standard 2-h-duration PMX. Further studies to investigate the survival benefits of long-duration PMX treatment are expected in the future.
Source of the infection that induces septic shock is important in evaluating a patient's prognosis. The three RCT (European pilot study, EUPHAS, and ABDO-MIX) and almost all studies published in Japan included patients with septic shock as a result of abdominal infections. The EUPHAS 2 registry was conducted by 57 centers collecting retrospective data for 357 patients with severe sepsis and septic shock. 25 The respiratory source (17.6%; 63 cases) was, in fact, the second most frequently observed clinical condition in the study.
The 28-day mortality in patients with respiratory infections (52.5%)
showed a trend toward a higher mortality rate than in those with abdominal infections (39.4%). Lower respiratory tract infections may have some differences compared to abdominal or urinary sepsis. In the discussion, they described that pulmonary sepsis seemed to respond less to the two sessions of endotoxin removal because source control is better achieved through antibiotic action and the resolution needs a longer time. However, in patients with intraabdominal sepsis, the source control is obtained through surgery and concomitant PMX treatment, achieving a more rapid resolution. 25 Kono et al. 36 reported that a longer duration of PMX is more efficacious for patients with acute exacerbation of interstitial pneumonia than a short duration. The longer duration of PMX might also improve the conditions of such patients with septic shock as a result of pulmonary infections. 
